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ORIGINAL ARTICLE
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ABSTRACT
Purpose: To assess the effect of additional magnetic resonance imaging (MRI) alongside the planning
computed tomography (CT) scan on target volume delineation in pancreatic cancer patients.
Material and methods: Eight observers (radiation oncologists) from six institutions delineated the
gross tumor volume (GTV) on 3DCT, and internal GTV (iGTV) on 4DCT of four pancreatic cancer
patients, while MRI was available in a second window (CTþMRI). Variations in volume, generalized
conformity index (CIgen), and overall observer variation, expressed as standard deviation (SD) of the dis-
tances between delineated surfaces, were analyzed. CIgen is a measure of overlap of the delineated
iGTVs (1¼ full overlap, 0¼no overlap). Results were compared with those from an earlier study that
assessed the interobserver variation by the same observers on the same patients on CT without MRI
(CT-only).
Results: The maximum ratios between delineated volumes within a patient were 6.1 and 22.4 for the
GTV (3DCT) and iGTV (4DCT), respectively. The average (root-mean-square) overall observer variations
were SD¼ 0.41 cm (GTV) and SD¼ 0.73 cm (iGTV). The mean CIgen was 0.36 for GTV and 0.37 for iGTV.
When compared to the iGTV delineated on CT-only, the mean volumes of the iGTV on CTþMRI were
significantly smaller (32%, Wilcoxon signed-rank, p< .0005). The median volumes of the iGTV on
CTþMRI were included for 97% and 92% in the median volumes of the iGTV on CT. Furthermore,
CTþMRI showed smaller overall observer variations (root-mean-square SD¼ 0.59 cm) in six out of eight
delineated structures compared to CT-only (root-mean-square SD¼ 0.72 cm). However, large local
observer variations remained close to biliary stents and pathological lymph nodes, indicating issues
with instructions and instruction compliance.
Conclusions: The availability of MRI images during target delineation of pancreatic cancer on 3DCT
and 4DCT resulted in smaller target volumes and reduced the interobserver variation in six out of eight
delineated structures.
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Introduction
Radiotherapy for pancreatic cancer aims at delivering a high
radiation dose to the tumor while minimizing the dose deliv-
ered to the organs at risk (OARs). Several developments have
improved the accuracy of radiotherapy of pancreatic cancer.
The introduction of intensity modulated radiotherapy and
volumetric modulated arc therapy enabled steep dose gra-
dients close to the tumor, reducing the dose to OARs [1].
Also, patient alignment has greatly improved with the intro-
duction of intratumoral fiducial markers combined with daily
cone-beam computed tomography (CBCT) [2,3]. Furthermore,
motion management has been improved with the introduc-
tion of 4D computed tomography (CT) [4] and breath hold-
ing [5]. One of the remaining major challenges in
radiotherapy for pancreatic cancer patients is precise and
accurate target volume definition [6–9].
So far, studies on delineation accuracy investigated delin-
eations on 3DCT in 1–2 patients with 11–25 observers [6–8],
except for one recent study in which clinical delineations of
60 patients were compared to a gold standard defined by a
team of experts [9]. However, no quantitative information
was reported on the interobserver conformity of the
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delineated volumes, or on local and overall observer varia-
tions expressed as standard deviations (SD). Such parameters
are especially relevant for determining appropriate planning
treatment volume margins [10] and quantifying improvement
in interobserver variation after intervention [11]. In an earlier
study with eight observers and four patients, we confirmed a
substantial interobserver variation when the tumor was
delineated on 3DCT and 4DCT based on these parameters
[12].
One of the reasons for this considerable interobserver vari-
ation may be the poor contrast between pancreatic tumors
and the surrounding tissue on CT images. Potentially, mag-
netic resonance imaging (MRI) provides better tumor visibility
[13,14]. For several other organs, MRI has been shown to
improve interobserver variation [15–17]. For pancreatic
tumors, delineations based on MRI were only studied in sin-
gle institute studies (1–3 observers), which did not quantify
the interobserver variation [18,19]. To our knowledge, no
multi-center study that assesses the value of MRI for target
volume delineation in pancreatic cancer patients is available.
The aim of this feasibility study was to evaluate the effect
of offering MRI alongside the planning CT for delineation of
the target volume in pancreatic cancer patients. In this study,
we quantify the interobserver variation and compare it to
our previously published results [12] on CT-based delineation
with the same eight observers and four patients.
Material and methods
In our previous study (CT-only) [12], eight observers (radi-
ation oncologists) from six Dutch institutions participating in
the PREOPANC trial [20] delineated target volumes of four
pancreatic cancer patients using only diagnostic and plan-
ning CTs. In the current study (CTþMRI), we asked the same
observers to repeat the delineations for the same patients,
now offering a diagnostic MRI alongside the CTs. All CT-only
data presented in this paper as comparison come from the
earlier study [12].
Patients
The same patients were selected as in the CT-only study [12].
In that study, we selected the first four patients with histo-
logically proven (borderline) resectable pancreatic ductal
adenocarcinoma who participated in the PREOPANC (EudraCT
number 2012-003181-40) trial [20] (radiochemotherapy arm)
and MIPA (NCT01989000) study. The patients gave written
informed consent to both studies, which were approved by
the local medical ethics committees (PREOPANC: Erasmus
Medical Center, Rotterdam; MIPA: Academic Medical Center,
Amsterdam).
Imaging
Patients underwent a diagnostic CT, MRI and planning CT
examination. The diagnostic CT scans (contrast-enhanced; CE)
were acquired as part of standard patient care at the refer-
ring hospitals. Experienced abdominal radiologists from our
institution reviewed these scans and considered them
adequate for diagnostic purposes.
After diagnosis, all patients received three markers (intra-
tumoral golden fiducial markers) that were visible on CT, but
not on MRI [2,21]. Furthermore, patients 1–3 received metallic
biliary stents, and patient 4 received percutaneous biliary
drainage. All were placed after the diagnostic CT, but before
the MRI and planning CT.
MRI was performed on an Ingenia 3T scanner (Philips
Healthcare, Best, the Netherlands) as part of the MIPA study.
Four MRI scans were obtained using various sequences:
T1-weighted spoiled gradient echo (T1W GE), CE T1W GE,
T2-weighted turbo spin echo (T2W TSE) and diffusion-
weighted imaging (DWI) for which the apparent diffusion
coefficient map was displayed (examples in Figure 1(e–h)).
The planning CT scans were acquired at our radiation
oncology department on a GE LightSpeed RT 16 scanner
(General Electric Company, Waukesha, WI, USA). Two plan-
ning CT scans were acquired, a CE 3DCT and a 4DCT. Several
image sets were reconstructed from the 4DCT scan: the 10
respiratory phases, average intensity projection (Ave-IP) and
maximum intensity projection (MIP). Further details of all
scans are discussed in the Supplementary Materials.
Delineation
Observers delineated the gross tumor volume (GTV) on the
3DCT (CE) and the internal GTV (iGTV) on the Ave-IP recon-
struction of the 4DCT. The GTV was defined as the macro-
scopically visible tumor and pathological lymph nodes. The
iGTV was defined as the GTV delineated on the Ave-IP recon-
struction, extended to encompass the GTV on the 10 respira-
tory phases of the 4DCT. The current study (CTþMRI),
consisted of a 3DCTþMRI and 4DCTþMRI stage, in which
the GTV and iGTV, respectively, were delineated under the
guidance of MRI. The results were compared to the results
from the 3DCT-only and 4DCT-only stages of the CT-only
study [12]. For both studies, observers received the same
instructions on what to delineate, taken from the PREOPANC
trial [20].
In both studies, observers received the Big Brother soft-
ware [22]. The software showed a primary window, in which
the iGTV was delineated, and a secondary window that
could display selected other available images (Table 1).
When viewed in the secondary window, the displayed slice
from the 3DCT and 4DCT image and cursor position was
linked to the primary window (i.e., same slice and a dot
indicating cursor position). Furthermore, observers had
access to the radiology reports of the diagnostic CT and, in
the CTþMRI study, the radiology reports of the MRI. These
reports, from experienced abdominal radiologists, described
the tumor extent. For the CT report, the associated patho-
logical lymph nodes were also described: two suspicious
locoregional lymph nodes in patient 2; ‘some’ (cited)
enlarged lymph nodes in patient 4, which were not charac-
terized further.
First, the software for the CT-only study was sent to all
observers. Four weeks after an observer returned their
924 O. J. GURNEY-CHAMPION
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CT-only delineations, that observer received a PowerPoint
document. In this document, the visibility of pancreatic
tumors on the abovementioned MRI scans was discussed for
nine pancreatic cancer patients (different from those
included in this study). Observers received the software for
the CTþMRI study at least six weeks after returning their CT-
only delineations. During delineation, the diagnostic CT and
MRI were not registered to the planning CT. As the pancreas
and other abdominal organs had deformed between the
three image sessions, a deformable registration would be
required. The use of deformable image registration for this
purpose is not widely validated. Therefore, we chose not to
register the images.
Figure 1. Example slices of GTV delineated on 3DCTþMRI (a) or 3DCT-only [12] (b) and iGTV delineated on the Ave-IP using 4DCTþMRI (c) or 4DCT-only [12] (d).
The MRI images (e–h) show the manually selected corresponding slice. The apparent diffusion coefficient map from the DWI acquisition is shown (h). T1W:
T1-weighted; GE: gradient echo; CE: contrast enhanced; T2W: T2-weighted; TSE: turbo spin echo; DWI: diffusion-weighted imaging.
Table 1. Overview of the images.
3DCTþMRI 3DCT-onlya 4DCTþMRI 4DCT-onlya
3DCT X X þ þ
4DCT Ave-IP – – X X
4DCT MIP – – þ þ
4DCT 10 phases – – þ þ
Diagnostic CTs þ þ þ þ
T1W GE þ – þ –
CE T1W GE þ – þ –
T2W TSE þ – þ –
DWIb þ – þ –
X: images in main window, used for delineation; þ: available in secondary
window; Ave-IP: average intensity projection; MIP: maximum intensity projec-
tion; T1W GE: T1-weighted gradient echo; CE: contrast enhanced; T2W TSE:
T2-weighted turbo spin echo; DWI: diffusion-weighted imaging.
aThese stages are from the CT-only study [12].
bThe apparent diffusion coefficient map of the DWI images was shown.
ACTA ONCOLOGICA 925
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CT1MRI
The analyses were performed using the Big Brother software
[22]. A resident radiation oncologist (EV) visually assessed the
individually delineated iGTVs. She counted the number of
observers who included the stents/drain, markers and patho-
logical lymph nodes in the delineated volume. The average
volume of the iGTVs, and generalized conformity index
(CIgen) [23] per patient was calculated with the Big Brother
software. CIgen is the sum over all observer pairs of their
common volume (delineated by both observers), divided by
the sum over all observer pairs of their encompassing vol-
umes (delineated by at least one observer). CIgen is a meas-
ure of overlap of the iGTVs (1¼ full overlap, 0¼no overlap).
A median surface was defined using Big Brother. This surface
was the 3D closed surface comprising the volume that was
included in the iGTV by at least 50% of the observers. The
median surface was sampled with approximately equidistant
(0.5mm) points. For each point, the perpendicular distances
from the median surface to the surfaces of the eight indi-
vidually delineated iGTVs were measured. If the surface of a
delineated iGTV was not within 2 cm, the distance to the
closest point on that surface was used instead. The SD over
these eight distances was used as a measure of local obser-
ver variation (local SD). The overall observer variation (overall
SD) was defined as the root-mean-square of all local SDs
[22]. Average overall SDs were calculated as root-mean-
square over all patients. To assess the dependence of the
CIgen and overall SD on individual observers, we reported the
range of values in a leave-one-out analysis. In this approach,
the analyses were repeated eight times, successively leaving
out one of the observers.
Comparison of CT1MRI with CT-only
The results were compared to results from the CT-only study
[12]. All statistical analyses were performed using SPSS (ver-
sion 22.0.0.2, IBM, New York, NY, USA). Plots were made with
GraphPad Prism (version 5.00, GraphPad Software, San Diego,
CA, USA). To test for differences in mean delineated target
volumes, CIgen and mean overall SD, we used a two-sided
Wilcoxon signed-rank test between the CT-only and CTþMRI
studies (significance level a¼ 0.05). Histograms of the local
SDs per patient were compared between the CT-only study
and CTþMRI study. Finally, we compared the 3D median
surfaces from both studies and calculated for each median
surface from the CT-only study the percent of the volume
surrounded by the median surface of the CTþMRI study and
vice versa.
Results
Observers had on average 10.6 years (range 3–17 years) of
experience in radiotherapy. Observer 4 (12 years of experi-
ence in radiotherapy) only just started treating pancreatic
cancer. The remaining seven had an average of 5.4 years
(range 2–12.5 years) of experience treating pancreatic cancer.
These observers saw an average of 3.5 pancreatic cancer
patients (range 1–7.5 patients) per year. All observers had
experience with MRI in radiotherapy, and four had experi-
ence with MRI for pancreatic cancer.
CT1MRI
The maximum ratio between delineated target volumes
within one patient was 6.1 for 3DCTþMRI and 22.4 for
4DCTþMRI (Figure 1(a,c)). The mean CIgen was 0.36 for
3DCTþMRI and 0.31 for 4DCTþMRI (Table 2). The mean
(root-mean-square over all patients) overall observer variation
expressed by overall SD was 0.41 cm for 3DCTþMRI and
0.73 cm for 4DCTþMRI. Despite the instructions that patho-
logical lymph nodes should be included in the iGTV, the dif-
ferent lymph nodes were only delineated by 1–4 (range) out
of eight observers (Supplemental Table B.I). Furthermore, the
iGTVs showed large variations close to stents/drain, in par-
ticular in patient 3 in whom four out of eight observers
Table 2. Average volume, CIgen, and overall observer variation.
3DCTþMRI 3DCT-onlya 4DCTþMRI 4DCT-onlya
Average volume (cm3)
Patient 1 13.3 (6.1–32.5) 36.7 (14.0–75.9) 19.3 (10.5–52.5) 41.8 (11.9–90.0)
Patient 2 9.1 (4.5–13.8) 20.3 (7.1–45.2) 18.5 (3.0–51.3) 20.6 (4.7–67.9)
Patient 3 5.7 (1.9–11.8) 10.4 (2.9–19.9) 11.0 (3.2–26.9) 32.4 (5.7–93.6)
Patient 4 53.4 (34.8–96.0) 52.3 (34.2–76.7) 59.8 (38.2–76.9) 65.5 (21.5–119.1)
Mean: 20.4 29.9 27.13 40.07
CIgen
Patient 1 0.31 (0.29–0.39) 0.34 (0.31–0.37) 0.25 (0.23–0.29) 0.29 (0.26–0.31)
Patient 2 0.34 (0.32–0.42) 0.22 (0.20–0.27) 0.17 (0.15–0.21) 0.20 (0.17–0.27)
Patient 3 0.23 (0.20–0.36) 0.34 (0.30–0.37) 0.20 (0.17–0.26) 0.16 (0.12–0.19)
Patient 4 0.56 (0.53–0.61) 0.59 (0.57–0.62) 0.61 (0.59–0.62) 0.45 (0.42–0.50)
Mean 0.36 0.37 0.31 0.27
Overall SD (cm)
Patient 1 0.43 (0.36–0.44) 0.70 (0.47–0.72) 0.57 (0.53–0.60) 0.71 (0.60–0.72)
Patient 2 0.40 (0.28–0.43) 0.84 (0.70–0.88) 1.11 (0.87–1.14) 0.90 (0.37–0.90)
Patient 3 0.40 (0.35–0.40) 0.48 (0.42–0.51) 0.62 (0.50–0.66) 0.89 (0.77–0.94)
Patient 4 0.43 (0.37–0.45) 0.43 (0.38–0.44) 0.39 (0.35–0.40) 0.68 (0.58–0.70)
Root-mean-square 0.41 0.63 0.73 0.80
SD: standard deviation (0: full agreement); CIgen: generalized conformity index (0: no agreement, 1: full agreement).
Between brackets, range of volumes (average volume) and range of leave-one-out analyses (overall SD and CIgen).
aThese results are from the CT-only study [12].
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included the stent for 4DCTþMRI and five out of eight for
4DCTþMRI (Supplemental Table B.II).
Comparison of CT1MRI with CT-only
Delineated iGTVs were 32% smaller when based on CTþMRI
compared to CT-only (p< .0005, Z¼3.826, Figures 1(a–d)
and 2 and Table 2). There was no significant difference in
mean CIgen between the CTþMRI study (CIgen¼ 0.34) and
CT-only study (CIgen¼ 0.32; p¼ .844, Z¼0.280). The mean
overall observer variation was not significantly smaller in the
CTþMRI study (root-mean-square overall SD¼ 0.59 cm) than
in the CT-only study (0.72 cm; p¼ .078, Z¼1.820). However,
they were smaller in six out of eight delineated structures
(three out of four GTVs, three out of four iGTVs).
Making MRI available decreased the local observer vari-
ation particularly in regions that had a large (>1 cm) local SD
in the CT-only study (Figure 3). The histograms of local SD
reflect this effect (Supplemental Figure C1). These histograms
show shorter tails at high local SD for CTþMRI compared to
CT-only, especially for the GTV of patients 1 and 2, and the
iGTV of patients 3 and 4.
The median delineated surfaces of the iGTV of patient 2
each consisted of two separate volumes (except during the
3DCTþMRI stage), one encompassing the main tumor and
one encompassing a suspicious portocaval lymph node
(Figure 3). As only 4–5 observers delineated this lymph node
(Supplemental Table B.I), the local observer variation was
large for that part of the median surface (Figure 3, patient 2:
local SD >1 cm). Excluding this lymph node from the median
surface resulted in an overall SD¼ 0.72 cm (leave-one-out
range: 0.50–0.75 cm) in the 3DCT-only stage, 0.86 cm (0.44–0.
91 cm) in the 4DCTþMRI stage and 0.49 cm (0.37–0.51 cm) in
the 4DCT-only stage.
The median surfaces from the CTþMRI study were on
average for 97% and 92% included within the median surfa-
ces of the CT-only study for the GTV (3DCT) and iGTV (4DCT),
respectively (Figure 4). Vice versa, the median surfaces from
the CT-only study were for 56% and 64% included within the
median surface of the CTþMRI study.
The number of observers who delineated a specific lymph
node only varied by a maximum of one observer between the
two studies (Supplemental Table B.I). An exception was the
portocaval lymph node in patient 2, which was delineated by
two observers in the 3DCTþMRI stage, instead of 4–5 observ-
ers in all other stages. There was a poor agreement in all stages
on whether to include stents/drains in the iGTV (Supplemental
Table B.II). There was a small difference (< 17% for all patients)
between the CTþMRI study and CT-only study in the percent-
age of markers included in the iGTV (Supplemental Table B.III),
except in patient 3. In patient 3, the markers were less often
included for CTþMRI than for CT-only delineations.
Discussion
We are the first to study the effect of offering MRI alongside
the planning CT for delineation of pancreatic tumors in a
multi-center setting. When MRI was available, the precision,
represented by the overall SD, improved in six out of eight
delineated structures. Furthermore, the volumes of the iGTV
decreased significantly. The overlap of delineated iGTV, repre-
sented by CIgen, remained similar, despite the smaller
Figure 2. Scatter plots of the volume of the delineated iGTV on 3DCTþMRI (a), 4DCTþMRI (b), 3DCT-only (c) and 4DCT-only (d) per patient per observer. Median
and interquartile ranges are indicated. Observer colors in the online article correspond to Figure 1(a–d). Graphs (c) and (d) are from Versteijne et al. [12].
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Figure 3. The local observer variation (local SD) projected on the median surfaces of the iGTV for 3DCTþMRI (a), 3DCT-only (b), 4DCTþMRI (c) and 4DCT-only (d).
Colors correlate to the local SD, with white (online: red) indicating local SD 9.4mm. Volumes are viewed posterior of the patient (dummy). Note that for patient 2,
the portocaval lymph node was included in b–d. Figures b and d are from Versteijne et al. [12].
Figure 4. For each patient, median surfaces for CTþMRI study (orange and light blue in the online version) and the CT-only study (red and dark blue in the online
version) are shown.
928 O. J. GURNEY-CHAMPION
D
ow
nl
oa
de
d 
by
 [R
ad
bo
ud
 U
niv
ers
ite
it N
ijm
eg
en
] a
t 0
4:0
6 0
2 O
cto
be
r 2
01
7 
volumes. These findings suggest an extra value of adding
MRI for pancreatic tumor delineation. However, even with
MRI the observer variations were large compared to other
organs, and in the future better education, more elaborate
delineation instructions and better instruction compliance are
required to further improve delineations.
In our study, as well as in other studies [18,19], delineated
target volumes in pancreatic cancer patients were smaller
when (partially) based on MRI than when based on CT-only.
Similar findings have been reported for other types of cancer
[15,16]. There are two possible causes for this decrease in
volume. The tumor volume size could be overestimated on
CT due to poor tumor contrast and uncertain tumor bounda-
ries. Furthermore, tumor size could be underestimated on
(CTþMRI). Therefore, appropriate clinical target volume (CTV)
margins should be determined.
We assessed the number of interactions done in Big
Brother with the various MRI sequences and found that
observers focused on the CE T1W GE (results not shown). In
one study [24], pancreatic tumor sizes were underestimated
when assessed on CE MRI. In a different study [18], it was
shown that delineations of pancreatic cancer tumors on MRI
were larger when based on DWI than when based on CE
T1W GE images. Future protocol instructions for MRI-based
tumor delineation should be developed taking into account
these issues. In addition, detailed education for observers on
what the different MRI sequences visualize may stimulate the
use of the other sequences being offered and hence further
improve delineations.
The addition of MRI mainly decreased the local SD in
regions that had large local observer variation (local SD
>1 cm). The fact that less decrease was seen in other regions of
low local observer variation could be a result of the MRI images
not being registered to the planning CT images. Translating
the MRI information to the CT images may be challenging for
the observers. Potentially, registration of the CT and MRI
images decreases the overall observer variation further.
Clear instructions and consensus on what to delineate
decreases interobserver variation, as was shown in various
organs [11]. In our study, no specific instructions on whether
to include stents/drains into the iGTV were given. The large
variation on including stents suggests the necessity of such
instructions. Our delineation instructions did state that patho-
logical lymph nodes should be included in the iGTVs. The
large variation concerning the inclusion of lymph nodes in
the iGTV suggests that observer compliance is also import-
ant. As these confusions affected both the CT-only and
CTþMRI studies (Supplemental Tables B.I–B.III), we believe
they did not influence the comparison between the CT-only
and CTþMRI delineations.
Several limitations were associated with this paper. Due to
the relatively large amount of pancreatic tumor delineations
done (four patients, four times) in a relatively short time,
observers may have improved their skills between both stud-
ies. Furthermore, despite the gap of at least six weeks
between both studies, observers may have recognized
patients during the CTþMRI study. Both factors could result
in smaller observer variation for CTþMRI. Furthermore, the
MRI was not obtained as part of the radiotherapy treatment.
When MRI is obtained for radiation treatment, different set-
tings or sequences may be preferred with higher resolutions,
such as e.g., alternating repetition time balanced steady-state
free precession imaging, as alternative for T2W TSE [25].
Similar to findings for other organs [15–17], we found that
the overall observer variation decreased when MRI was avail-
able during delineation. Consequently, potentially smaller
planning treatment volume margins can be used for
CTþMRI delineations than for CT-only delineations. However,
due to the exploratory nature of this research, the overall SD
was based on a small patient group and, therefore, does not
necessarily represent typical overall SDs for the pancreatic
cancer patient population. This study should be repeated
using more patients to quantify treatment margins.
In conclusion, this exploratory study demonstrates the
feasibility of adding MRI during treatment planning. The
availability of MRI images to CT during target volume delin-
eation for pancreatic cancer improved (decreased) the overall
observer variation for six out of eight structures and resulted
in smaller delineated volumes compared to CT-only delinea-
tion. Yet, large local observer variations existed close to the
biliary stent and/or pathological lymph nodes, indicating
issues with instructions and instruction compliance.
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